The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
The efficacy and safety of pembrolizumab in advanced cervical cancer—A real world treatment study in an irish healthcare setting.
 
Iseult Browne
Travel, Accommodations, Expenses - Astellas Oncology (Inst)
 
David William Fennelly
No Relationships to Disclose
 
John Crown
Employment - OncoMark
Stock and Other Ownership Interests - OncoMark
Honoraria - Amgen; Boehringer Ingelheim; Eisai; Genomic Health; MSD Oncology; Novartis Ireland Ltd.; Pfizer; Puma Biotechnology; Roche; Seagen; Vertex
Consulting or Advisory Role - Boehringer Ingelheim; Eisai; G1 Therapeutics; G1 Therapeutics; Pfizer; Puma Biotechnology; Roche; Seagen; Vertex
Speakers' Bureau - Eisai; Genomic Health; Pfizer
Research Funding - Boehringer Ingelheim (Inst); Eisai (Inst); Puma Biotechnology (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - WO2020011770 (A1) - A method of predicting response to treatment in cancer patients
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; MSD; Novartis Ireland Ltd.; Pfizer; Roche
 
Hazel Murray
No Relationships to Disclose